Stockscreener 앱 받기
498.04
0.22%
1.07
시장 영업 전:
502.00
3.96
+0.80%
전일 마감가:
$496.97
열려 있는:
$496.97
하루 거래량:
231.52K
Relative Volume:
0.67
시가총액:
$11.31B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-19.83
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
+0.44%
1개월 성능:
-17.38%
6개월 성능:
+58.92%
1년 성능:
+53.38%
1일 변동 폭
$492.01
$504.00
1주일 범위
$483.55
$511.94
52주 변동 폭
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
498.04 | 11.29B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Biotech Madrigal gives 3,049 options, 13,145 RSUs to new staff - Stock Titan
CEO Moves: What are analysts price targets for Madrigal Pharmaceuticals IncTreasury Yields & Real-Time Market Sentiment Reports - baoquankhu1.vn
Lobbying Update: $280,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Emerald Advisers LLC Sells 2,371 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals announces grant of inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grant Of Inducement Award Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
New accounting chief at Madrigal lands stock and options deal - Stock Titan
Taub Rebecca, director at Madrigal, sells $1.09m in MDGL stock - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Rebecca Taub Sells 2,238 Shares - MarketBeat
Kelley, Madrigal Pharmaceuticals general counsel, sells $344,172 in MDGL By Investing.com - Investing.com Canada
MDGL: Analyst Jonathan Wolleben Raises Price Target to $745 | MD - GuruFocus
Citizens Jmp Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $745.00 - MarketBeat
10 Analysts Have This To Say About Madrigal Pharmaceuticals - Benzinga
Citizens raises Madrigal Pharmaceuticals stock price target on strong Rezdiffra launch - Investing.com Canada
How Pfizer Ervogastat License Deal Will Impact Madrigal Pharmaceuticals (MDGL) Investors - Sahm
Short Covering: Is Madrigal Pharmaceuticals Inc benefiting from innovation trendsRate Hike & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
EULAV Asset Management Buys 20,000 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease - Sahm
Lobbying Update: $80,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Madrigal Pharmaceuticals (NASDAQ:MDGL) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
SG Americas Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs By Investing.com - Investing.com Canada
Director Friedman sells Madrigal (MDGL) shares for $154,347 By Investing.com - Investing.com Canada
Rebecca Taub sells Madrigal (MDGL) shares worth $9.6 million By Investing.com - Investing.com Canada
JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Paul Friedman Sells 24,520 Shares - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells $9,617,384.00 in Stock - MarketBeat
MADRIGAL PHARMACEUTICALS Executives Sell Over $21 Million in Company Stock - TradingView — Track All Markets
Madrigal Pharmaceuticals (BIT:1MDGL) Price Target Increased by 11.17% to 537.90 - Nasdaq
ETF Watch: Is Madrigal Pharmaceuticals Inc a top pick in the sectorJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
How Madrigal Pharmaceuticals Inc. (MDGL) Affects Rotational Strategy Timing - Stock Traders Daily
MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Finviz
Madrigal Pharmaceuticals stock bolstered by Truist’s positive view on Pfizer asset acquisition - Investing.com Canada
Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
Pfizer inks licensing deal with Madrigal for MASH candidate - MSN
Madrigal’s $50M Pfizer Deal Sparks a New MASH Drug Power Play - MyChesCo
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum - Yahoo Finance
Madrigal expands its MASH pipeline - The Pharma Letter
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe DowngradeWhat's Changed - Yahoo Finance
Is Madrigal Pharmaceuticals Inc. stock a safe investment in uncertain marketsPortfolio Value Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Madrigal Pharmaceuticals (MDGL) Secures Global License for Ervog - GuruFocus
Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat - marketscreener.com
Pfizer in pact with Madrigal for MASH drug (MDGL:NASDAQ) - Seeking Alpha
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline - Investing.com
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline By Investing.com - Investing.com India
Madrigal Pharmaceuticals Expands Pipeline with Exclusive License Agreement for Ervogastat, Enhancing Leadership in MASH Therapies - Quiver Quantitative
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor - marketscreener.com
What Madrigal Pharmaceuticals (MDGL)'s Valuation-Driven Analyst Downgrade Means For Shareholders - Sahm
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.46%
0.83%
자본화:
|
볼륨(24시간):